Nabil Ahmed
Overview
Explore the profile of Nabil Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
5669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Somes L, Lei J, Yi X, Chamorro D, Shafer P, Gad A, et al.
Mol Ther
. 2025 Feb;
PMID: 39980195
Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes of breast cancer to treat due to a lack of effective targeted therapies. Chimeric antigen receptor (CAR)-T cells hold...
2.
Landi D, Navai S, Brock R, Fousek K, Nawas Z, Sanber K, et al.
Cancer Res Commun
. 2025 Feb;
PMID: 39973814
The efficacy of CAR T-cells (CART) in solid tumors is limited by immune inhibition. In our study, we observed that effector cytokines mediated the upregulation of the PD-L1 immune-checkpoint in...
3.
Ross A, Puri K, Johnson T, Correa L, John T, Friend B, et al.
Pediatr Blood Cancer
. 2025 Jan;
72(4):e31557.
PMID: 39833487
Background: Immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR)-modified T-cell therapy, have shown efficacy in pediatric B-cell acute lymphoblastic leukemia (B-ALL) and are being investigated for other malignancies....
4.
Gad A, Morris J, Godret-Miertschin L, Montalvo M, Kerr S, Berger H, et al.
Sci Adv
. 2025 Jan;
11(2):eadq8114.
PMID: 39792660
Chimeric antigen receptor T cells (CART) targeting CD19 through CD28.ζ signaling induce rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB.ζ-CART. We reasoned that molecular dynamics...
5.
Wunderle V, Wilhelm T, Boukeileh S, Gossen J, Margreiter M, Sakurov R, et al.
Eur J Immunol
. 2024 Dec;
55(2):e202451348.
PMID: 39676406
Mast cell (MC)-driven allergic diseases are constantly expanding and require the development of novel pharmacological MC stabilizers. Allergen/antigen (Ag)-triggered activation via crosslinking of the high-affinity receptor for IgE (FcεRI) is...
6.
Visvanathan A, Saulnier O, Chen C, Haldipur P, Orisme W, Delaidelli A, et al.
Cell
. 2024 Jul;
187(17):4733-4750.e26.
PMID: 38971152
We identify a population of Protogenin-positive (PRTG) MYC NESTIN stem cells in the four-week-old human embryonic hindbrain that subsequently localizes to the ventricular zone of the rhombic lip (RL). Oncogenic...
7.
Miller A, Daum R, Wang T, Wu M, Tat C, Pfeiffer T, et al.
Cytotherapy
. 2024 May;
26(9):1026-1032.
PMID: 38819365
Background Aims: The success of chimeric antigen receptor (CAR) T-cell therapy in treating B-cell malignancies has led to the evaluation of CAR T-cells targeting a variety of other malignancies. Although...
8.
Draper B, Bowers C, Vassalou E, Greppi A, Anderson J, Ahmed N, et al.
STAR Protoc
. 2024 May;
5(2):103078.
PMID: 38781075
Here, we present a protocol for preclinical evaluation of locoregionally delivered CAR T cells in patient-derived xenograft models of primary, metastatic, and recurrent brain tumors. We provide instructions for isolating...
9.
Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, et al.
Nat Cancer
. 2024 May;
5(6):954.
PMID: 38778179
No abstract available.
10.
Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, et al.
Nat Cancer
. 2024 May;
5(7):1010-1023.
PMID: 38750245
Chimeric antigen receptor (CAR) T cells used for the treatment of B cell malignancies can identify T cell subsets with superior clinical activity. Here, using infusion products of individuals with...